ArticleCureus2025
Fibrin Glue for Sutureless PreserFlo Surgery: A Case Series.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose To evaluate the efficacy of sutureless PreserFlo MicroShunt insertion using fibrin glue for conjunctival closure and scleral band fixation in patients with advanced glaucoma in Cairns, Australia. Methods A retrospective case series evaluated seven patients undergoing urgent PreserFlo MicroShunt insertion at Cairns Hospital (March 2023 to November 2024). VeraSeal fibrin glue was used for conjunctival closure, with scleral band fixation in three cases. Pre- and post-operative intraocular pressure (IOP), visual acuity (VA), and ocular hypotensive medications were measured. Primary outcomes included intraocular pressure (IOP) and glaucoma medication reduction at six months and non-routine post-operative reviews within the first month. Secondary outcomes were complications and revision surgery needs. Success was defined as >20% IOP reduction at six months. Results Seven patients (mean age 74 years, range 54-87 years; three neovascular glaucoma, three primary open-angle glaucoma, one aphakic glaucoma) were included. Mean IOP decreased from 34.9±16.5 mmHg to 11.3±3.8 mmHg at six months. Medications reduced from a mean of 3.3 (range 3-5) to 0.1 (range 0-1). Non-routine visits averaged 3.7 (range 3-4). Complications included transient hypotony (n=1), tube exposure (n=1, managed with fibrin glue), macrohyphema (n=3), and pre-existing Snuff syndrome (n=2). No glue-related complications occurred. Scleral band fixation cases showed well-formed blebs without extrusion. Conclusions Sutureless PreserFlo MicroShunt with fibrin glue and scleral band fixation effectively reduces IOP and medication use with minimal complications and follow-up. Further studies are needed to validate this approach.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.